Precision medicine in the diagnosis and treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia

被引:5
作者
Chen, Jing-Liang
Jiang, Yuan-Hong
Lee, Cheng-Ling
Kuo, Hann-Chorng [1 ]
机构
[1] Buddhist Tzu Chi Med Fdn, Hualien Tzu Chi Hosp, Dept Urol, 707 Sect 3,Chung Yang Rd, Hualien, Taiwan
来源
TZU CHI MEDICAL JOURNAL | 2020年 / 32卷 / 01期
关键词
Benign prostatic hyperplasia; Bladder outlet obstruction; Lower urinary tract symptoms; Overactive bladder; Voiding dysfunction; ALPHA-BLOCKER THERAPY; OVERACTIVE BLADDER; VIDEOURODYNAMIC ANALYSIS; TRANSURETHRAL INCISION; COMBINATION THERAPY; VOIDING DYSFUNCTION; URETHRAL RESISTANCE; OUTLET OBSTRUCTION; STORAGE SYMPTOMS; EXTENDED-RELEASE;
D O I
10.4103/tcmj.tcmj_107_19
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Male lower urinary tract symptoms (LUTSs) are highly prevalent in men and the incidence increases with aging. The pathophysiology of male LUTSs might be bladder outlet dysfunctions such as bladder neck (BN) dysfunction, benign prostatic obstruction, and poor relaxation of external sphincter and bladder dysfunctions such as detrusor overactivity (DO), detrusor underactivity, DO, and inadequate contractility. Male LUTSs include voiding and storage symptoms, and precision diagnosis should not be done based on the symptoms alone. Videourodynamic study provides a thorough look at the bladder and bladder outlet and can clearly demonstrate the underlying pathophysiology when the initial medication fails to relieve LUTS. Medical treatment should be given based on the underlying pathophysiology of LUTS, and surgical intervention to remove prostate should only be performed when a definite bladder outlet obstruction due to prostatic obstruction has been confirmed by invasive urodynamic study.
引用
收藏
页码:5 / 13
页数:9
相关论文
共 63 条
  • [1] The many faces of impaired bladder emptying
    Andersson, Karl-Erik
    [J]. CURRENT OPINION IN UROLOGY, 2014, 24 (04) : 363 - 369
  • [2] Urinary bladder contraction and relaxation: Physiology and pathophysiology
    Andersson, KE
    Arner, A
    [J]. PHYSIOLOGICAL REVIEWS, 2004, 84 (03) : 935 - 986
  • [3] Antimuscarinics for treatment of overactive bladder
    Andersson, KE
    [J]. LANCET NEUROLOGY, 2004, 3 (01) : 46 - 53
  • [4] Integrating the patient risk profile in the management of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH)
    Artibani, W
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2004, 3 (04) : 1 - 6
  • [5] Alpha-blocker therapy can be withdrawn in the majority of men following initial combination therapy with the dual 5α-reductase inhibitor dutasteride
    Barkin, J
    Guimaraes, M
    Jacobi, G
    Pushkar, D
    Taylor, S
    van Vierssen Trip, OB
    [J]. EUROPEAN UROLOGY, 2003, 44 (04) : 461 - 466
  • [6] THE AMERICAN-UROLOGICAL-ASSOCIATION SYMPTOM INDEX FOR BENIGN PROSTATIC HYPERPLASIA
    BARRY, MJ
    FOWLER, FJ
    OLEARY, MP
    BRUSKEWITZ, RC
    HOLTGREWE, HL
    MEBUST, WK
    COCKETT, ATK
    BLAIVAS, JG
    WEIN, AJ
    [J]. JOURNAL OF UROLOGY, 1992, 148 (05) : 1549 - 1557
  • [7] Chen JL., 2006, JUTA, V17, P41
  • [8] Evaluation of patient outcome after discontinuation of alfuzosin treatment for benign prostatic hyperplasia: a multicentre, prospective study
    Chung, J. H.
    Lee, J. Y.
    Kang, D. H.
    Jo, J. K.
    Lee, J. W.
    Lee, S. H.
    Lee, K. S.
    Kim, T. H.
    Han, J. H.
    Lee, S. W.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2013, 67 (09) : 870 - 875
  • [9] The Efficacy of Additive Tolterodine Extended Release for 1-Year in Older Men With Storage Symptoms and Clinical Benign Proastatic Hyperplasia
    Chung, Shiu-Dong
    Chang, Hsiao-Chun
    Chiu, Bin
    Liao, Chun-Hou
    Kuo, Hann-Chorng
    [J]. NEUROUROLOGY AND URODYNAMICS, 2011, 30 (04) : 568 - 571
  • [10] EAU guidelines on benign prostatic hyperplasia (BPH)
    de la Rosette, JJMCH
    Alivizatos, G
    Madersbacher, S
    Perachino, M
    Thomas, D
    Desgrandchamps, F
    De Wildt, M
    [J]. EUROPEAN UROLOGY, 2001, 40 (03) : 256 - 263